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Only a few cases of “myelomalacia with spinal cord atrophy” after intrathecal methotrexate and cytosine arabinoside (ara-C) alone or in combination have been reported [1-9]. 
In general, it is a chronic, cumulative dose-related condition but the 
onset may be acute also. Paraplegia in the context of malignancy 
has many potentially different causes and diagnostic techniques or 
procedures that clarify the diagnosis are helpful to the treatment 
team. In this paper, we describe a patient in whom acute onset 
paraplegia developed after the intrathecal administration of 
combined methotrexate, ara-C, and hydrocortisone. The magnetic 
resonance imaging (MRI) suggestive of myelomalacia was 
dramatically abnormal and unique for this condition.
CASE REPORT
A 6-year-old male child diagnosed as acute lymphoblastic leukemia 
was on treatment according to MCP 841 protocol. On the 17th day 
of 6th cycle maintenance phase chemotherapy (6-mercaptopurine 
and weekly methotrexate), he developed severe headache and 
vomiting. Lumbar puncture was done, and blasts were found in the 
cerebrospinal fluid (CSF). Bone marrow aspiration and biopsy did 
not show any blasts. The patient was diagnosed as “early isolated 
central nervous system relapse.”
Triple intrathecal chemotherapy with methotrexate, 
hydrocortisone, and cytarabine was planned weekly, till three 
consecutive normal documented CSF examinations. After 5th cycle 
of intrathecal chemotherapy, the patient developed weakness in 
both lower limbs with urinary retention. The weakness progressed 
over 3 days to complete paraplegia with power 0/5, absence of deep 
tendon reflexes and absent plantar reflex. Sensory perception was 
normal.
The CSF examination at this time showed no blast cells or 
pleocytosis and a very mild increase in protein. CSF culture for 
bacteria, fungus, and tuberculosis produced no growth. CSF viral 
culture for poliovirus, echovirus, Coxsackie virus, herpes simplex 
virus, and mumps virus was negative. The previous (4th cycle) CSF 
examination was also negative for blast. Hypocalcemia was noted 
(serum calcium 6.2 mg/dl) and corrected by intravenous calcium 
infusion. MRI spine showed decreased signal intensity in the central 
portion of lower dorsal and upper lumbar spinal cord suggestive 
of spinal cord atrophy and myelomalacia. There were neither any 
leukemic infiltrations of the spinal cord which can explain paraplegia 
nor any spinal cord hematoma (Figs. 1 and 2).
Subsequently, he developed weakness in both upper limbs with 
difficulty in respiration. He was intubated and given ventilator 
support for 7 h. The patient finally succumbed to death as paraplegia 
progressed to quadriplegia and respiratory failure. The progressively 
deteriorating condition of the patient did not allow us to do an MRI 
brain; hence, leukoencephalomalacia could not be confirmed.
DISCUSSION
The possible causes of spinal cord atrophy and myelomalacia are 
leukemic infiltrates, spinal cord hematoma, transverse myelitis, 
bacterial or viral meningitis, and hypocalcemia [1-12]. The possible 
causes of myelomalacia such as leukemic infiltration of spinal cord, 
transverse myelitis, and spinal cord hematoma were excluded by 
MRI as well as the absence of pleocytosis in CSF. The paraplegia 
due to hypocalcemia is of gradual onset and is non-progressive 
and generally responds to correction of hypocalcemia which was 
not seen in our case. We finally concluded that patient developed 
chemotherapy-induced myelopathy, based on specific MRI findings 
and exclusion of other possible causes.
The syndrome of myelopathy associated with intrathecal 
administration of` chemotherapy has been reported since the 
introduction of this mode of treatment in the mid-1960s [10]. The 
clinical syndrome is characterized by leg weakness, urinary retention 
or incontinence, and paresthesia. Some patients report pain in the 
hips or low back. Sometimes the weakness and sensory level ascend, 
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resulting in quadriplegia and death [7]. Pain seems to be present in 
patients with absent reflexes, suggesting nerve root involvement as 
the cause of this symptom. The symptoms may occur as acute onset 
(within minutes) to as long as 6 months after intrathecal therapy [9]. 
Those with immediate paralysis generally lose reflexes and experience 
pain, and the disease involves the nerve roots [6]. When the onset is 
delayed, the disease involves the spinal cord [3,4]. The prognosis 
is variable: Some patients recover completely, whereas others make 
an incomplete or no recovery. Usually, the maximal involvement 
is in the thoracic cord [3]. In a systematic analysis of spinal cord 
disease in the children who died of acute lymphatic leukemia, Price 
described an entity called “subacute necrotizing leukomyelopathy.” 
This was observed in 20 of 65 spinal cords examined. 75% of the 
children receiving a cumulative dose of 200 mg or more of intrathecal 
methotrexate showed white matter disease [11].
The pathogenesis of paraplegia after intrathecal chemotherapy 
remains obscure. Several hypotheses postulated to explain it. The 
acute syndrome occurring immediately after injection seems related 
to the preservative used in the diluents. This complication has not 
been reported since its cause was recognized. Second, the location of 
the disease matches the intraspinal penetration of labeled intrathecal 
methotrexate administered experimentally. Hence, a direct toxic effect 
of the drug has been postulated [8]. Third, the possible mechanism 
can be high CSF drug level. The syndrome develops in patients who, 
for one or another reason have high CSF drug levels. When CSF 
methotrexate levels were measured prospectively, side effects and 
paraplegia correlated with the highest CSF level [12]. High levels 
can also be obtained by more frequent administration; one patient 
was reported in whom the syndrome developed after 5 consecutive 
days of intrathecal administration [5]. The lesions may be due to 
local folate deficiency related to methotrexate penetration into the 
spinal cord. However, this does not explain how ara-C produces the 
lesion. The diagnosis of paraplegia occurring in the context of treated 
malignancy remains difficult.
CONCLUSION
Intrathecal methotrexate and/or cytarabine-induced acute 
myelomalacia is relatively lesser reported complication from India. 
These cases are increasing in number as more facilities are available 
to treat pediatric cancers. We should always keep in mind that these 
drugs can lead to severe adverse effects which can cost the life of 
the patient also. A baseline MRI brain and spine should be ordered 
to each patient before starting the high dose/combination intrathecal 
chemotherapy.
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Figure 1: Magnetic resonance imaging (contrast) dorsolumbar 
region showing spinal cord atrophy
Figure 2: Magnetic resonance imaging (T1) dorsolumbar region 
showing spinal cord atrophy
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